Inhaled Steroids and Control of Severe Asthma (INHALE)
Inhaled Steroids and Control of Severe Asthma: Comparison of the AKITA Technology Versus Conventional MDI (INHALE)
Sponsor: Activaero GmbH
Terminated
6 out of 20 patients were included. The trend towards the treatment of severe asthma has meanwhile developed in a different direction, so that there is no longer any intention to pursue the study objective mentioned here.
Listed as NCT01197482, this observational or N/A phase trial focuses on Severe Persistent Asthma and remains terminated or withdrawn. Sponsored by Activaero GmbH, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Dec 2020 — Jan 2021 [monthly]
Terminated
Status: Unknown Status → Terminated
▶ Show 4 earlier versions
-
Jan 2019 — Dec 2020 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Activaero GmbH
- University of Giessen
For direct contact, visit the study record on ClinicalTrials.gov .